Ustekinumab in severe complicated erythrodermic psoriasis: rapid clearing, safety, and sustained remission

Authors

  • Xanthippe-Argyro Koutsoukou,

    1. 2nd Department of Dermatology and Venereology, Attikon University General Hospital, University of Athens, Medical School, Athens, Greece
    Search for more papers by this author
    • These two authors have contributed equally to this manuscript.
  • Evangelia Papadavid,

    Corresponding author
    1. 2nd Department of Dermatology and Venereology, Attikon University General Hospital, University of Athens, Medical School, Athens, Greece
    • Address correspondence and reprint requests to: Evangelia Papadavid, MD, PhD., Assistant Professor in Dermatology, 2nd Department of Dermatology and Venereology, Attikon University General Hospital, University of Athens, Medical School, 12462 Athens, Greece, or email: papadavev@yahoo.gr.

    Search for more papers by this author
    • These two authors have contributed equally to this manuscript.
  • Konstantinos Theodoropoulos,

    1. 2nd Department of Dermatology and Venereology, Attikon University General Hospital, University of Athens, Medical School, Athens, Greece
    Search for more papers by this author
  • Dimitris Rigopoulos

    1. 2nd Department of Dermatology and Venereology, Attikon University General Hospital, University of Athens, Medical School, Athens, Greece
    Search for more papers by this author

Abstract

Erythrodermic psoriasis is a severe type of psoriasis associated with comorbidities and high mortality. Patients with erythrodermic psoriasis need hospitalization and systemic treatment. Conventional drugs and biologic agents may not manage to control refractory and complicated erythrodermic psoriasis resulting from treatment failure. Ustekinumab, a human monoclonal antibody against interleukin-12 and 23, seems to be an effective therapeutic option in erythrodermic psoriasis whenever other therapies have failed.

Ancillary